Chris Hill remembers his 14-year-old son, Colin, as a boy who loved to run. “I look back at him as a kid, he always loved running,” Hill recalled. “He always loved being fast. That was kind of his ...
Cytokinetics To Announce Second Quarter Results On August 6, 2026. SOUTH SAN FRANCISCO, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is ...
Everyone benefits when biopharmaceutical companies create a culture that can gather and apply patient feedback ...
New research mapped disease-causing variants in the ACTN2 protein, identifying a critical hotspot linked to hypertrophic ...
Scientists have found that the 'sudden' cardiac death condition related to high profile deaths or major medical episodes of sports stars including ...
CEO Robert Blum joins Julie Hyman on Market Catalysts to discuss the company's first commercial product, Myqorzo, a treatment ...
Scientists have found that the 'sudden' cardiac death condition related to high profile deaths or major medical episodes of sports stars including Fabrice Muamba, Christian Erikson and Mark-Vivian Foe ...
Scientists have found that the "sudden" cardiac death condition related to high-profile deaths or major medical episodes of ...
Concomitant hypertension in patients with hypertrophic cardiomyopathy shows a greater burden of myocardial fibrosis on ...
Morning Overview on MSN
A new drug offered fresh hope for people with a common heart-thickening disease
The Food and Drug Administration approved Myqorzo, a once-daily pill containing the active ingredient aficamten, for adults ...
A new drug offers hope for people with hypertrophic cardiomyopathy, the world's most common inherited heart disease. The ...
The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia Therapeutics and Braveheart Bio the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results